Insmed (NASDAQ:INSM) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Key Points

• Insmed’s revenue strongly beat expectations: Third-quarter revenue rose 268.4% year over year to $524.4 million, exceeding the $499.1 million consensus, although the company’s $0.46 per-share loss missed estimates by $0.07.
• BRINSUPRI and ARIKAYCE drove growth: BRINSUPRI revenue reached $400.1 million, while ARIKAYCE generated $124.4 million; Insmed raised its 2026 revenue guidance for both products.
• Management expects further financial improvement: Insmed ended the quarter with about $1.1 billion in cash and anticipates reaching positive cash flow in 2027, supported by product growth and its pipeline, including the TPIP program.

Insmed (NASDAQ:INSM - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $524.43 million for the quarter, compared to analysts' expectations of $499.06 million. During the same period in the prior year, the firm earned ($1.75) EPS. Insmed's revenue for the quarter was up 268.4% compared to the same quarter last year.

Here are the key takeaways from Insmed's conference call:

• BRINSUPRI’s launch continues to materially outperform expectations: Third-quarter revenue reached $400.1 million, up 29% sequentially, and the product surpassed $1 billion in its first four full quarters. Insmed raised 2026 BRINSUPRI guidance to $1.35 billion-$1.4 billion.
• ARIKAYCE also delivered steady growth and faces a major potential market expansion. Third-quarter revenue rose 9% year over year to $124.4 million, prompting higher 2026 guidance of $460 million-$470 million; FDA priority review for a broader MAC lung disease label has a January 28, 2027 action date.
• Insmed expects to reach cash-flow positivity in 2027. The company ended the quarter with approximately $1.1 billion in cash, while management said BRINSUPRI’s growth should improve operating leverage even as investments continue across the pipeline.
• The long-term pipeline remains a significant growth driver, led by TPIP. TPIP’s four Phase 3 studies are advancing, with the PH-ILD trial more than 35% enrolled and ahead of schedule; management estimates more than $6 billion in peak sales potential, although approvals and clinical outcomes remain uncertain.
• Insmed is pursuing a large but still unquantified expansion of BRINSUPRI’s opportunity in COPD and asthma patients with undiagnosed comorbid bronchiectasis. AI diagnostic tools, imaging studies, physician education and other initiatives are underway, with initial findings expected around mid-2027; management characterized the opportunity as substantial but acknowledged that adoption will take time.

Insmed Stock Up 14.8%

Insmed stock traded up $14.32 during mid-day trading on Thursday, hitting $111.30. The company had a trading volume of 8,572,547 shares, compared to its average volume of 2,969,150. The business has a fifty day moving average of $113.29 and a 200 day moving average of $126.28. The stock has a market cap of $24.31 billion, a price-to-earnings ratio of -27.05 and a beta of 0.83. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. Insmed has a 1 year low of $90.39 and a 1 year high of $212.75.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raised revenue outlook: Insmed increased its 2026 revenue guidance for BRINSUPRI to $1.35 billion–$1.40 billion and for ARIKAYCE to $460 million–$470 million. The company also launched BRINSUPRI in Japan, expanding the product’s commercial opportunity. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Revenue growth exceeded expectations: Third-quarter revenue rose 268.4% year over year to $524.4 million, above the roughly $499.1 million analyst consensus. BRINSUPRI generated $400.1 million, up 29% from the prior quarter, while ARIKAYCE revenue increased 9% year over year to $124.4 million. Insmed Raises FY26 Revenue Outlook for BRINSUPRI and ARIKAYCE
• Positive Sentiment: Quarterly loss narrowed: Insmed reported a loss of $0.46 per share, improving from a $1.75 loss a year earlier. Although the result missed analyst expectations, the year-over-year improvement and accelerating product revenue supported the bullish reaction. Insmed Inc Q3 Loss Narrows
• Neutral Sentiment: Unusually active options trading: Traders purchased 7,706 call options, 121% above the average volume of 3,483 contracts. The activity suggests increased bullish speculation, but options volume alone does not confirm a sustained change in investor expectations.
• Negative Sentiment: EPS missed estimates: The quarterly loss of $0.46 per share was wider than the consensus loss of $0.39, highlighting continuing profitability risk for the biotechnology company. Insmed Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: Price target reduction: Raymond James lowered its Insmed price target from $187 to $173, potentially limiting sentiment even though the revised target remains above the current trading range. Raymond James Cuts Target for Insmed

Insider Transactions at Insmed

In related news, Director David Brennan sold 25,000 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Roger Adsett sold 239,850 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on INSM shares. The Goldman Sachs Group began coverage on Insmed in a report on Thursday, September 24th. They set a "buy" rating and a $188.00 price target for the company. Morgan Stanley reduced their price objective on Insmed from $218.00 to $213.00 and set an "overweight" rating on the stock in a report on Wednesday, October 21st. Raymond James Financial set a $173.00 price target on shares of Insmed in a report on Tuesday, October 20th. UBS Group reiterated a "buy" rating on shares of Insmed in a research note on Thursday, October 8th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Insmed in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $197.26.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed's lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.